GlassScriptPhysician profile
Christine Uy
NPI 1669663969
$6,718.74
in general payments reported to CMS, 2019-2025
38 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $1,287 · 2021: $1,095 · 2022: $1,040 · 2023: $703 · 2024: $1,115 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.31 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,214.84 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $746.42 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $399.93 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Amgen INC. | $376.07 | 2020-2025 | Tepezza, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.51 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $300.78 | 2021-2025 | Korlym |
| Abbott Laboratories | $296.63 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Horizon Therapeutics Plc | $270.98 | 2019-2023 | Tepezza |
| Amarin Pharma, INC. | $267.86 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $260.22 | 2021-2025 | Unithroid |
| Dexcom, INC. | $249.83 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $212.18 | 2020-2025 | Synthroid |
| Radius Health, INC. | $152.37 | 2019-2024 | Tymlos |
| Ibsa Pharma INC. | $149.64 | 2019-2025 | Tirosint, Flector, Licart |
| Insulet Corporation | $138.51 | 2021-2025 | Omnipod |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $126.88 | 2019-2023 | |
| Grt US Holding, INC. | $125.00 | 2022 | |
| Allergan, INC. | $125.00 | 2019 | |
| Genzyme Corporation | $105.00 | 2019 | |
| Nevro Corp. | $86.23 | 2023-2024 | Senza |
| Beta Bionics, INC. | $85.98 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $76.34 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $73.93 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $66.50 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $52.82 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $50.19 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $45.74 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $44.66 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $43.94 | 2023-2024 | Strensiq |
| Neurocrine Biosciences, INC. | $43.62 | 2025 | |
| Astellas Pharma US INC | $40.57 | 2025 | Veozah |
| Sequel Med Tech, LLC | $35.80 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $30.38 | 2025 | Imcivree |
| Ascensia Diabetes Care US INC. | $25.42 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $23.03 | 2022 | |
| Averitas Pharma INC. | $18.80 | 2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $14.63 | 2022 | |
| Antares Pharma, INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Uy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.